Pseudocholinesterase Deficiency: Difference between revisions
(Created page with "{{Stub Notice}}") |
(What is pseudocholinesterase deficiency. How to interpret lab tests to assess for it.) |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
Pseudocholinesterase deficiency is an acquired or inherited defect in the pseudocholinesterase enzyme, resulting in prolonged effects of pseudocholinesterase metabolized agents including succinylcholine, mivacurium, and ester local anesthetics. Duration of prolonged action of the aforementioned drugs depends upon a homozygous or heterozygous atypical pseudocholinesterase enzyme. The degree of pseudocholinesterase deficiency in at risk patients can be objectively assessed by measuring the dibucaine number (% of PChE enzyme activity inhibited by dibucaine) and the PChE enzyme activity. An interpretation of these tests is as follows: | |||
Normal values: Total PChE (2900-7100 U/L), Dibucaine number of at least 80 | |||
Variable risk of prolonged paralysis: Normal to decreased PChE activity, Dibucaine number 30-80 | |||
High risk of prolonged paralysis: Decreased PChE activity, Dibucaine number <30 | |||
Treatment of prolonged paralysis from administration of triggering agents in a patient with pseudocholinesterase deficiency includes mechanical ventilation and respiratory support until resolution of neuromuscular blockade. | |||
{{Stub Notice}} | {{Stub Notice}} | ||
[https://pubmed.ncbi.nlm.nih.gov/31082076/ Pseudocholinesterase Deficiency] | |||
[https://ltd.aruplab.com/Tests/Pub/0020159 Pseudocholinesterase, Dibucaine Inhibition]] | |||
[https://pubmed.ncbi.nlm.nih.gov/32992329/ Pseudocholinesterase Deficiency Considerations: A Case Study] | |||
[https://pubmed.ncbi.nlm.nih.gov/22051140/ Plasma pseudo cholinesterase deficiency leading to seven hour apnoea in a child undergoing adeno-tonsillectomy] | |||
[https://pubmed.ncbi.nlm.nih.gov/10614702/ A case of pseudocholinesterase deficiency in the neonate] | |||
Latest revision as of 18:55, 17 November 2022
Pseudocholinesterase deficiency is an acquired or inherited defect in the pseudocholinesterase enzyme, resulting in prolonged effects of pseudocholinesterase metabolized agents including succinylcholine, mivacurium, and ester local anesthetics. Duration of prolonged action of the aforementioned drugs depends upon a homozygous or heterozygous atypical pseudocholinesterase enzyme. The degree of pseudocholinesterase deficiency in at risk patients can be objectively assessed by measuring the dibucaine number (% of PChE enzyme activity inhibited by dibucaine) and the PChE enzyme activity. An interpretation of these tests is as follows:
Normal values: Total PChE (2900-7100 U/L), Dibucaine number of at least 80
Variable risk of prolonged paralysis: Normal to decreased PChE activity, Dibucaine number 30-80
High risk of prolonged paralysis: Decreased PChE activity, Dibucaine number <30
Treatment of prolonged paralysis from administration of triggering agents in a patient with pseudocholinesterase deficiency includes mechanical ventilation and respiratory support until resolution of neuromuscular blockade.
This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.
Go to the Main Page to see the Topic Outline.
Go to the Generalized Suggested Outline for information on case-specific details for each page.
Go to the Test Page for examples on how to use references in the page.
Relevant Article Depot:
Pseudocholinesterase Deficiency
Pseudocholinesterase, Dibucaine Inhibition]
Pseudocholinesterase Deficiency Considerations: A Case Study